IINN (Inspira Technologies) חוב כולל להון

Inspira Technologies Oxy (IINN) faces regulatory challenges and a lack of current revenue typical for single-product biotechs. The business relies on the development of ART systems for non-invasive blood oxygenation, which reduces patient mortality. This chart on the GURU.Markets platform shows a total debt-to-equity ratio of 0.62. Patents for unique oxygenation methods ensure high margins and future free cash flow.

This ratio measures the proportion of debt obligations relative to equity, allowing investors to assess financial leverage and the extent of the business's dependence on external financing. By analyzing the company's debt-to-equity ratio, one can determine how sustainably Inspira Technologies Oxy absorbs R&D expenses and regulatory costs during the preparation period for the certification of oxygenation systems.